Co-Diagnostics, Inc. (CODX) Free cash flow
- Free cash flow · 12 months (USD): Value $-27.47M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -3808.03%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-27.47M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-27.10M − $367.37K ≈ $-27.47M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -3808.03% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-27.47M ÷ $721.39K × 100 ≈ -3808.03% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-27.10M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.57× | Operating cash flow / net income. Period ending 2026-06-30. $-27.10M ÷ $-47.16M ≈ 0.57× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -27.10M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 367.37K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -27.47M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 721.39K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -47.16M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-27.47M | (m) | $-27.10M | $367.37K | (m) | $721.39K | (m) | $-47.16M | (m) | (m) | -3808.03% | 0.57× |
| 2026-03-31 | $-28.99M | (m) | $-28.24M | $750.15K | (m) | $718.17K | (m) | $-48.50M | (m) | (m) | -4036.41% | 0.58× |
| 2025-12-31 | $-29.84M | (m) | $-29.14M | $700.05K | (m) | $622.49K | (m) | $-46.90M | (m) | (m) | -4793.17% | 0.62× |
| 2025-09-30 | $-31.81M | (m) | $-31.17M | $641.07K | (m) | $507.89K | (m) | $-32.18M | (m) | (m) | -6263.08% | 0.97× |
| 2025-06-30 | $-33.23M | (m) | $-32.49M | $740.40K | (m) | $1.00M | (m) | $-35.99M | (m) | (m) | -3311.30% | 0.90× |
| 2025-03-31 | $-29.85M | (m) | $-29.41M | $437.97K | (m) | $3.50M | (m) | $-35.86M | (m) | (m) | -853.39% | 0.82× |
| 2024-12-31 | $-29.90M | (m) | $-29.16M | $748.35K | (m) | $3.92M | (m) | $-37.64M | (m) | (m) | -763.78% | 0.77× |
| 2024-09-30 | $-26.84M | (m) | $-25.70M | $1.14M | (m) | $7.32M | (m) | $-41.28M | (m) | (m) | -366.65% | 0.62× |
| 2024-06-30 | $-25.44M | (m) | $-24.24M | $1.20M | (m) | $9.14M | (m) | $-37.57M | (m) | (m) | -278.43% | 0.65× |
| 2024-03-31 | $-26.24M | (m) | $-24.65M | $1.59M | (m) | $6.68M | (m) | $-38.89M | (m) | (m) | -392.97% | 0.63× |
| 2023-12-31 | $-23.45M | (m) | $-22.08M | $1.37M | (m) | $6.81M | (m) | $-35.33M | (m) | (m) | -344.20% | 0.62× |
| 2023-09-30 | $-22.51M | (m) | $-21.31M | $1.19M | (m) | $4.66M | (m) | $-42.56M | (m) | (m) | -483.16% | 0.50× |
| 2023-06-30 | $-14.79M | (m) | $-13.60M | $1.19M | (m) | $7.30M | (m) | $-37.94M | (m) | (m) | -202.69% | 0.36× |
| 2023-03-31 | $-7.95M | (m) | $-6.74M | $1.21M | (m) | $12.12M | (m) | $-31.71M | (m) | (m) | -65.57% | 0.21× |
| 2022-12-31 | $5.14M | (m) | $6.57M | $1.43M | (m) | $34.22M | (m) | $-14.24M | (m) | (m) | 15.02% | -0.46× |
| 2022-09-30 | $14.20M | (m) | $15.46M | $1.26M | (m) | $53.22M | (m) | $15.17M | (m) | (m) | 26.68% | 1.02× |
| 2022-06-30 | $24.66M | (m) | $25.85M | $1.19M | (m) | $78.22M | (m) | $28.00M | (m) | (m) | 31.52% | 0.92× |
| 2022-03-31 | $35.69M | (m) | $36.62M | $926.50K | (m) | $100.56M | (m) | $40.47M | (m) | (m) | 35.49% | 0.90× |
| 2021-12-31 | $40.41M | (m) | $41.08M | $669.46K | (m) | $97.89M | (m) | $36.66M | (m) | (m) | 41.28% | 1.12× |
| 2021-09-30 | $55.14M | (m) | $56.16M | $1.02M | (m) | $104.63M | (m) | $41.97M | (m) | (m) | 52.70% | 1.34× |
| 2021-06-30 | $52.26M | (m) | $53.21M | $951.09K | (m) | $96.35M | (m) | $46.22M | (m) | (m) | 54.24% | 1.15× |
| 2021-03-31 | $40.96M | (m) | $41.77M | $813.59K | (m) | $93.03M | (m) | $51.44M | (m) | (m) | 44.03% | 0.81× |
| 2020-12-31 | $27.39M | (m) | $28.17M | $774.40K | (m) | $74.55M | (m) | $42.48M | (m) | (m) | 36.74% | 0.66× |
| 2020-09-30 | $6.25M | (m) | $6.60M | $341.90K | (m) | $47.52M | (m) | $27.94M | (m) | (m) | 13.16% | 0.24× |
| 2020-06-30 | $-3.44M | (m) | $-3.18M | $265.76K | (m) | $25.74M | (m) | $8.09M | (m) | (m) | -13.37% | -0.39× |
| 2020-03-31 | (m) | (m) | $-5.49M | (m) | (m) | $1.76M | (m) | $-5.89M | (m) | (m) | (m) | 0.93× |
| 2019-12-31 | $-5.64M | (m) | $-5.53M | $113.25K | (m) | $214.97K | (m) | $-6.20M | (m) | (m) | -2622.80% | 0.89× |
| 2019-09-30 | $-4.99M | (m) | $-4.87M | $115.86K | (m) | $117.23K | (m) | $-6.41M | (m) | (m) | -4256.00% | 0.76× |
| 2019-06-30 | $-4.93M | (m) | $-4.84M | $84.42K | (m) | $85.49K | (m) | $-6.30M | (m) | (m) | -5761.47% | 0.77× |
| 2019-03-31 | (m) | (m) | $-4.48M | (m) | (m) | $33.62K | (m) | $-6.33M | (m) | (m) | (m) | 0.71× |
| 2018-12-31 | $-4.12M | (m) | $-4.08M | $41.34K | (m) | $39.91K | (m) | $-6.27M | (m) | (m) | -10326.41% | 0.65× |
| 2018-09-30 | $-4.15M | (m) | $-4.11M | $40.85K | (m) | (m) | (m) | $-5.83M | (m) | (m) | (m) | 0.71× |
| 2018-06-30 | $-4.53M | (m) | $-4.48M | $51.39K | (m) | (m) | (m) | $-8.08M | (m) | (m) | (m) | 0.55× |
| 2018-03-31 | $-3.86M | (m) | $-3.76M | $97.95K | (m) | (m) | (m) | $-7.56M | (m) | (m) | (m) | 0.50× |
| 2017-12-31 | $-3.34M | (m) | $-3.21M | $129.31K | (m) | (m) | (m) | $-6.96M | (m) | (m) | (m) | 0.46× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-1.32M | (m) | $-1.31M | $12.24K | (m) | (m) | (m) | $-1.93M | (m) | (m) | (m) | 0.68× |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |